SunnyBay Biotech

MCF-7 human breast cancer cells strongly express pro-metastatic CK-19

SunnyBay Biotech CEO Feng Wang-Johanning pictured in the lab

Our approach

Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome.

After finding HERV‑K, a family of HERVs, expressed in a multitude of solid cancers, the team at SunnyBay has generated specialized therapeutics capable of targeting these cancers without affecting normal cells.

The team

SunnyBay’s key players have spent over 20 years researching HERV‑K.

Meet the team »

SunnyBay Biotech Chief Scientific Officer Gary Johanning pictured standing next to a liquid nitrogen tank

Want to learn more?

SunnyBay Biotech is developing therapeutic and bispecific antibodies, cell‑based therapies, and vaccines toward the fight against cancer.